Anti-PD-1/PD-L1 antibody restores antitumor immune responses by disrupting the interactions between PD-1 and its ligand, PD-L1, thereby providing effective antitumor effects by augmenting the body’s own immune activity against the tumor. This evidence concerns the gene PDCD1 and neoplasm.